Gain Therapeutics, Inc. (GANX) — SEC Financial Statements & Analysis

Gain Therapeutics, Inc. (GANX) is a pharmaceutical preparations company, incorporated in DE. Gain Therapeutics, Inc. trades on Nasdaq as: GANX. Gain Therapeutics, Inc. (GANX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Gain Therapeutics, Inc. carries a market cap of $87.05M, a P/E ratio of -4.33x, a P/B ratio of 7.71x, a P/S ratio of 445.74x, an enterprise value of $74.27M, and an EV/EBITDA multiple of -3.87x. On profitability, it posts an operating margin of -39602.68%, a net margin of -39143.72%, a Return on Equity (ROE) of -268.30%, a Return on Assets (ROA) of -159.22%, and a Return on Invested Capital (ROIC) of -218.98%. Per share, it reports EPS of $-0.47, diluted EPS of $-0.47, free cash flow per share of $-0.44, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 8.14% year-over-year, and EPS growth of -23.48% year-over-year. On the balance sheet, it maintains a current ratio of 4.36x, a quick ratio of 3.87x, working capital of $11.54M, a debt-to-equity ratio of 0.37x, a debt ratio of 0.27, an interest coverage ratio of -61.13x, free cash flow of $-18.95M (TTM), and net debt of $-12.78M. Figures sourced from SEC EDGAR.

Market Cap

$87.05M

P/E TTM

-4.33x

EPS TTM

$-0.47

P/B TTM

7.71x

ROE TTM

-268.30%

ROA TTM

-159.22%

Debt To Equity

0.37x

Free Cash Flow TTM

$-18.95M

Net Revenue TTM Growth 1Y

-100.00%

Data as of 2026-06-30 · Source: SEC EDGAR